Ptc Therapeutics (PTCT) Liabilities and Shareholders Equity (2012 - 2026)

Ptc Therapeutics' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 8.05% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $11.0 billion (up 36.05% YoY), while the FY2025 annual figure was $2.9 billion, up 70.01% from the prior year.
• Liabilities and Shareholders Equity was $2.9 billion for Q1 2026 at Ptc Therapeutics, down from $2.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 billion in Q4 2025 to a low of $1.3 billion in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $2.0 billion across 5 years, with a median of $1.8 billion in 2022.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slipped 25.83% in 2023, then jumped 70.01% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.7 billion in 2022, then advanced by 11.14% to $1.9 billion in 2023, then declined by 10.06% to $1.7 billion in 2024, then surged by 70.01% to $2.9 billion in 2025, then fell by 1.02% to $2.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.9 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.